- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
Studies spanning industry-leading hematologic malignancies portfolio and pipeline with new research in solid tumor therapies to highlight precision medicine and targeted therapy strategies
European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response [1]
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study Other data presented demonstrate the long-term safety profile of STELARA® (ustekinumab) in bio-naïve and bio-failure patients living with inflammatory bowel disease
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
COMPASS open label extension study results support the long-term use of XARELTO® plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence of the benefit of DPI for CAD and/or PAD patients at high risk of cardiovascular (CV) events
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation TREMFYA is the first fully human IL-23 inhibitor indicated for adults with moderate to severe plaque psoriasis and adults with active psoriatic arthritis
New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empathy for People Living with Depression
Depression Looks Like Me Provides a Safe Space to Elevate the Experiences of the Community and Provide Resources for Adults Living with Hard-to-Treat Forms of Depression
MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia
Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa’s scientific capacity as a global hub for discovery research